Lonza Signs Manufacturing Deal with Immune Pharmaceuticals

Lonza says it has signed an exclusive contract for the production of Immune Pharmaceuticals’ (Tel Aviv, Israel) human immunoglobulin monoclonal antibody, Bertilimumab, under investigation for the potential treatment of several inflammatory disorders. Lonza will produce phase 2 clinical trial material at its mammalian development and manufacturing facility, under the terms of the deal. Immune is a biopharmaceutical company focused on the development of next generation monoclonal antibodies addressing unmet medical needs in the treatment of cancer and...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers